Abstract: The paper investigates the applicability of an advanced modern control method related to control of tumor growth under angiogenic inhibition. In order to describe the physiological process, a simple mathematical model was applied consisting of two states, the volume of the tumor and the inhibitor value. Extended Kalman Filter (EKF) was applied to estimate the unmeasurable state (inhibitor level). Linear Parameter Varying (LPV) models are used both at controller design (difference based control oriented LPV model) and EKF development (LPV model) level as well. We have used the Tensor Product (TP) model transformation accompanied by Linear Matrix Inequality (LMI) based optimization method in order to design a Parallel Distributed Compensator (PDC) kind TP-LPV-LMI controller considering additive disturbances (on both states) and sensor noise as well. Despite the assumed unfavorable effects the TP-LPV-LMI controller performed well achieving low final tumor volume and less totally injected inhibitor level.
INTRODUCTION
Targeted Molecular Therapies (TMTs) are recently developed innovative cancer treatment opportunities and can be applied for more personalized therapy regarding cancer provision. The aim of TMTs is to inhibit a given biological mechanisms of the cancer, Charlton and Spicer (2016) . Compared to the classical treatments -e.g. chemotherapy, radiotherapy, surgical intervention -the TMTs are less harmful; moreover, their specificities allow targeting directly important mechanisms of the tumor, Xing and Lisong (2017) .
The current study focuses on a specific TMT, the control of tumor growth by angiogenic inhibition, i.e. blocking blood vessel formation in the tumor. The phenomena is connected to a well-known property of tumors: beyond a certain level due to the lack of nutrients tumors can grow only by creating own blood vessels. The dominant way to form own vessels is the production of angiogenic factors (signal transducers) -the so-called vascular endothelial growth factor (VEGF) -by which they can catalyze the formation of new blood vessels, Vasudev and Reynolds (2014) . In order to "tame" the given tumor it is possible to inhibit this phenomena causing the "starvation" of the tumor and inhibiting its growing. One of the mostly used angiogen inhibitor is the bevacizumab (avastin) Abdalla et al. (2018) , considered for this study as well. The physiological process of angiogenesis can be modeled and controlled by control engineering methods. The main goal of the therapy is to reach the smallest tumor volume by using as small amount of drug as possible. Many investigations have been done in the last decade to analyze the problem and provide some solution: Sápi (2015) ; Lobato et al. (2016) ; Drexler et al. (2017b) ; Klamka et al. (2017) ; Drexler et al. (2017c,d) . However, there are still open questions to be answered like handling the nonlinearities or parameter uncertainties.
One possible solution is the application of LPV framework, since it allows the use of linear control techniques by effective handling of nonlinearities; moreover, the parameter uncertainties can be handled as well (White et al. (2013) ; Kovács (2017) ). In addition, a useful technique is the TP model transformation, which is able to represent the LPV functions (and systems) as TP models optimizing the LPV vertex. During the transformation, the goals of the control can be formulated via LMIs and the processes can be executed together leading to a TP-LPV-LMI controller (Boyd et al. (1994) ; Kuti et al. (2017b) ; Baranyi et al. (2013) ).
The current study points out an LPV-based solution for a novel model (Drexler et al. (2017a,c,d) ) in control oriented form. The framework effectively handles the nonlinearity and parameter uncertainty being comparable with the classical robust control solutions (Sápi (2015) ).
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The paper is structured as follows: first, the applied mathematical model and the developed LPV models are introduced. This is followed by the controller design steps including the TP model transformation, LMI formulations and EKF design. The third part presents our findings discussing the research results. Finally, we conclude our work and formulate further research direction possibilities.
MATHEMATICAL MODELS

Tumor Growth Model
In this study we have investigated the tumor growth model proposed by Drexler et al. (2017a,c,d) . The model consists of two state variables: the x 1 (t) [mm 3 ] tumor volume and the x 2 (t) [mg/kg] angiogen inhibitor level in the blood. The mathematical formulation is described by:
The (Drexler et al. (2017a) ). One can observe that x 1 (t) is limitlessly growing by the a scaling factor without inhibition. The steady-state of the model is:
It can be seen from (2) 
LPV Model Development
A general LPV model can be described in state-space form as follows (Sename et al. (2013) ; White et al. (2013) ):
(p(t))x(t) + B(p(t))u(t) y(t) = C(p(t))x(t) + D(p(t))u(t) ẋ(t) y(t) = S(p(t)) x(t) u(t) S(p(t)) = A(p(t)) B(p(t)) C(p(t)) D(p(t))
.
In this structure, A(t) ∈ R n×n , B(t) ∈ R n×m , C(t) ∈ R k×n and D(t) ∈ R k×m are the state, input, output and feed-forward matrices, while x(t) ∈ R n , y(t) ∈ R k and u(t) ∈ R m are the state, output and input vectors, respectively. The S(p(t)) ∈ R (n+k)×(n+m) represents the system matrix -which is the LPV function at the same time. The matrices are p(t) dependent, where p(t) is the parameter vector of the scheduling variables p i (t), namely,
We have used the (3) representation during the LPV model development. Two LPV models have been developed: one for control design purposes and the other one for the EKF design. Hence, we denoted their parameter vectors as p(t) ∈ R 2 and q(t) ∈ R 1 , respectively.
Model-A In case of the first LPV model, we have selected q(t) = x 1 (t) as scheduling variable from (1) through which the following LPV model can be obtained:
where
The q min is the approximation of the zero tumor volume. This is physiologically meaningful as to the target of TMTs is not to eliminate the tumor itself, but to "tame" it. The q max is in accordance with our previous investigations (Sápi (2015) ). Model-A has been used for the EKF design.
Model-B
We have developed a difference based control oriented LPV model for controller design purposes. We aimed to apply PDC kind state-feedback control as it directly models the error to be eliminated and it is not necessary to apply reference compensation beside. In this case a simple state transformation have been applied:
The new state variables model the error dynamics, namely, they describe the deviation of the original states from given reference states. In this way, the reference for the control will be ∆r = 0 2×1 , which is equivalent with the zero deviation of the state variables of the original model from the state variables of the reference system. Hence, the aim of the control becomes ∆x(t) = [x 1 (t), x 2 (t)] , namely, ∆x(t) → 0, while t → ∞. The transformation of (1) and the new model is described by:
. (5) The state-space description of (5) becomes as follows:
Here, p 1 (t) = 
−3 which is the approximation of a/b and needed to keep the controllability of the model. This is a consequence of (1), namely, the inhibitor level has to be higher than a/b in order to decrease the tumor volume. p 1,max is selected based on previous investigations (Sápi (2015) 
CONTROLLER DESIGN
The TP Model Transformation
The TP model transformation allows to represent arbitrary LPV models by optimizing the polytopic space of the LPV model. The finite element convex polytopic TP model can be described as follows:
The core tensor S ∈ R I1×I2×...×I R ×(n+k)×(n+m) consists of S i1,i2,...,i R linear time invariant (LTI) systems -which are the vertices of the polytope. The p(t) dependent vector valued weighting function w r (p r (t)) consists of w r,ir (p r (t)) (i r = 1...I R ) continuous convex weighting functions. The convexity criteria is satisfied, if ∀r, i, p r (t) :
w r,ir (p r (t)) = 1, which must be true during the application. We have used the Minimal Volume Simplex (MVS) convex hull representation (Kuti et al. (2017b) ). By applying it, the TP model approximating the original model inside the Ω hypercube with given accuracy depends on the applied sampling resolution in Ω (Kuti et al. (2017a,b) ; Hedrea et al. (2017) ). The necessary steps of the realization of the TP model transformation are available in Baranyi et al. (2013) ; Kuti et al. (2017a) ; Galambos and Baranyi (2015) .
A state-feedback kind controller can be described as follows (White et al. (2013) ):
m×n is the parameter dependent controller gain. The TP-based state-feedback kind polytopic controller becomes:
where G feedback tensor consists of G i1,i2,...,i R feedback gain matrices. Each G i belongs to a given S i vertex.
The connection between them is characterized by the w r (p r (t)), similar to (7). The resulting G(p(t)) controller is the convex combination of the gains G i in the vertices.
Linear Matrix Inequality based Controller Design
A polytopic LPV system can be represented asẋ(t) = A(p(t))x(t) + B(p(t))u(t), where the vertices of the poly-
where w r (p) is p-dependent convex weighting function (Baranyi et al. (2013) ). In accordance with Lyapunov's direct method, the Lyapunov function can be V (x(t)) = x Px = x X −1 x, at which the a given controller candidate can be described as:
The derivative of the Lyapunov function becomes as follows:
where "Sym" means symmetric term. (11) can be reformulated as:
The applied parameter dependent convex weighting function w(p(t)) is the same in case of the system and controller description, which allows the use PDC controller structure (Tanaka and Wang (2001) ; Baranyi et al. (2013) ).
For continuous polytopic LPV systems, the quadratically stabilizing PDC can be constructed by solving the following LMI optimization problem:
where M m×n i is the supplementary matrix, X n×n is a symmetric, positive definite matrix, while w i and w j are general polytopic weighting functions. The belonging control gain (9) is calculated as: (Tanaka and Wang (2001) ).
We have applied control input limitation, since the physiological reality requires the limitation of the amount of the injectable drug. Similarly to (13), this property can be formulated in the form of LMIs as follows (Boyd et al. (1994) ): min
where is guaranteed that u(t) 2 ≤ µ at t ≥ 0. For polytopic cases this holds, if x(0) lies on the polytope, which is satisfied, if x(t 0 ) 2 ≤ 1. The minimization problem can be extended to µ, if V (x(t 0 )) 2 ≤ 1.
The (13)- (14) optimization problem have been applied on Model-B from (6) and have been solved by using the YALMIP framework (Löfberg (2004) ) and MOSEK solver (MOSEK ApS (2015) ). Remark 2. Both (14) and EKF design requires preliminary knowledge about the states. The use of different starting points do not cause stability issues due to the slow sampling time. Moreover, the initial tumor size is assumed to be known.
Remark 3. We assumed that u(t) ≥ 0 in accordance with the physiological reality: negative control signal, i.e. drug aspiration from blood is not possible.
Kalman Filter Design
We have developed a continuous/discrete (mixed) EKF (Grewal and Andrews (2008) ). The physiological system is continuous, however, we have considered discrete time measurements. It has to be noted that we have applied the Model-A LPV model from (4). The considered sampling time was considered T = 1 day in conformity with (1).
The considered model for the EKF was the following:
where f = A A (p(t))x(t) + B A u(t) originates from (4) and
We have considered additive system disturbances and
) and R k = cov(v(k)) accordingly. The applied variances are arbitrarily selected (in the lack of available sensor technology), but in accordance with the phenomena.
The initial conditions have been considered the followings:
The a-priori (prediction) phase can be solved by the following differential equations and by considering that x(t k−1 ) =x k−1|k−1 and P(t k−1 ) = P k−1|k−1 :
where F(t) = ∂f ∂x x,u . The solution of (16) is applied in the a-posteriori (update) phase as:x k|k−1 =x(t k ) and
The Kalman gain K k can be calculated as follows:
Next, the following difference equation has to be solved, where I is the identity matrix in appropriate dimension: Figure 1 shows the final control structure. We have considered the original model as reference model in this study. In our future work we will investigate other reference models as well. ] -which leads that x 1 (t f inal ) < 1 due to the control framework. The additional d term was arbitrarily selected in conformity with the requirements.
Control Structure
The developed TP-LPV-LMI controller enforced the original nonlinear model to act as the selected reference model. Hence, x(t) = x ref (t), t → ∞, which is the same as
The unmeasurable state was estimated by the EKF. We have applied ∆x(t) =x(t) − x ref (t) for error signal generation, which was compared to ∆r = 0 as ∆e(t) = ∆r − ∆x(t). 
RESULTS
We have used Euler approximation during the simulations with T = 1 day sampling time. The sampling density of the parameter vector p(t) in the parameter domain Ω was s = [199, 199] -this sampling density provides good approximation of the original model according to our previous test.
Since x 1 (t) was assumed to be measurable, we considered that x 1 (t 0 ) = 30000 [mm 3 ] is available. The inhibitor level is zero before the beginning of the therapy, thus x 2 (t 0 ) = 0 [mg/kg]. The reference model has been considered as known and valid. In this way, its initial states can be arbitrarily -but reasonably -determined. We assumed that We assumed additional system disturbances (d 1 (t) and d 2 (t)) and we considered random additive measurement noise v k . As to our best knowledge, there is no available tumor "sensor", the magnitudes of the disturbances and noises have been arbitrarily selected to be comparable to the magnitude of the states and output. We have taken into account these unfavorable effects during the EKF design. . It can be seen that the d 1 (t) and d 2 (t) additive system disturbances reflected in the difference of the states. Despite the disturbances, the EKF was stable. The second subfigure shows the 2-norm based error as
, which is a concise description of the state error. At the beginning, the state deviances caused higher error, but due to the appropriate control action the difference decreased until 0.0131 at the end of the simulated time period. The third and fourth subfigures represent the error between the reference model and EKF as x ref (t) −x(t) 2 from day 0 to 70 and from day 70 to 120, respectively. Similarly to the previous case, the error in 2-norm sense decreased promptly after the higher period at the beginning. The disturbances and sensor noise are not visible due to the magnitude of the initial error. The lowest subfigure shows that despite the appeared disturbances and sensor noise, the EKF approached the reference system appropriately. 
t) − u(t).
As we already mentioned, the u ref was considered constant. The middle figure shows that there is a higher peak in u(t) at the beginning. This is a consequence of the state-feedback kind control action due to the initial state 
CONCLUSIONS
The study introduced the latest achievements regarding the automated control of tumor growth by using angiogenic inhibition.
The mathematical model applied consists of two states representing the tumor growth dynamics under antiangiogenic therapy. We have assumed that x 1 (t) is measurable directly. However, the second state needed to be estimated. We have implemented a mixed continuous/discrete EKF -which frequently appears in the literature regarding physiological systems -based on a simple LPV model.
For control design purposes we have developed an error dynamics based LPV model transformed into TP model form. The controller design was done by considering this model and by applying Lyapunov's second law and control IFAC LPVS 2018 Florianopolis, Brazil, September 3-5, 2018 541 input saturation through LMIs related to polytopic LPV models.
In this study, the original model has been considered as reference system. By using permanent reference control signal, the reference state trajectories were generated by it. The reference control signal was calculated in order to drive the reference states into the desired values.
The validation showed that the developed TP-LPV-LMI controller was able to provide appropriate control action despite the disturbances and noise. The control goal, namely, the tumor volume of the controlled system deceased under a certain -satisfactory -level.
As further step will investigate the use of other tumor growth models in the developed control framework to examine its capabilities. Moreover, we will develop more advanced reference generation possibilities in our future work, analyzing possibilities of reduced parameter uncertainty Precup et al. (2017) , the separation of the EKF and controller design and investigating the optimal controller design through the presented framework.
